Logo image of PDSB

PDS BIOTECHNOLOGY CORP (PDSB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PDSB - US70465T1079 - Common Stock

0.9042 USD
+0.01 (+1.22%)
Last: 12/26/2025, 8:09:31 PM
0.8843 USD
-0.02 (-2.2%)
After Hours: 12/26/2025, 8:09:31 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to PDSB. PDSB was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of PDSB have multiple concerns. PDSB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PDSB has reported negative net income.
In the past year PDSB has reported a negative cash flow from operations.
PDSB had negative earnings in each of the past 5 years.
PDSB had a negative operating cash flow in each of the past 5 years.
PDSB Yearly Net Income VS EBIT VS OCF VS FCFPDSB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -100.52%, PDSB is not doing good in the industry: 75.66% of the companies in the same industry are doing better.
The Return On Equity of PDSB (-369.02%) is worse than 74.72% of its industry peers.
Industry RankSector Rank
ROA -100.52%
ROE -369.02%
ROIC N/A
ROA(3y)-69.42%
ROA(5y)-56.3%
ROE(3y)-151.69%
ROE(5y)-107.33%
ROIC(3y)N/A
ROIC(5y)N/A
PDSB Yearly ROA, ROE, ROICPDSB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PDSB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PDSB Yearly Profit, Operating, Gross MarginsPDSB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for PDSB has been increased compared to 1 year ago.
PDSB has more shares outstanding than it did 5 years ago.
PDSB has a worse debt/assets ratio than last year.
PDSB Yearly Shares OutstandingPDSB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PDSB Yearly Total Debt VS Total AssetsPDSB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -9.88, we must say that PDSB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.88, PDSB is not doing good in the industry: 73.02% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.26 is on the high side and indicates that PDSB has dependencies on debt financing.
PDSB has a worse Debt to Equity ratio (1.26) than 78.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Altman-Z -9.88
ROIC/WACCN/A
WACCN/A
PDSB Yearly LT Debt VS Equity VS FCFPDSB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

PDSB has a Current Ratio of 2.09. This indicates that PDSB is financially healthy and has no problem in meeting its short term obligations.
PDSB has a worse Current ratio (2.09) than 75.85% of its industry peers.
PDSB has a Quick Ratio of 2.09. This indicates that PDSB is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.09, PDSB is not doing good in the industry: 73.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 2.09
PDSB Yearly Current Assets VS Current LiabilitesPDSB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.91% over the past year.
EPS 1Y (TTM)29.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.59% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.77%
EPS Next 2Y15.18%
EPS Next 3Y10.06%
EPS Next 5Y19.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PDSB Yearly Revenue VS EstimatesPDSB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M
PDSB Yearly EPS VS EstimatesPDSB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PDSB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PDSB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PDSB Price Earnings VS Forward Price EarningsPDSB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PDSB Per share dataPDSB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.18%
EPS Next 3Y10.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PDSB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PDS BIOTECHNOLOGY CORP

NASDAQ:PDSB (12/26/2025, 8:09:31 PM)

After market: 0.8843 -0.02 (-2.2%)

0.9042

+0.01 (+1.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners10.8%
Inst Owner Change-24.31%
Ins Owners1.85%
Ins Owner Change0%
Market Cap47.35M
Revenue(TTM)N/A
Net Income(TTM)-34.88M
Analysts82.22
Price Target7.65 (746.05%)
Short Float %3.57%
Short Ratio2.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.22%
Min EPS beat(2)11.76%
Max EPS beat(2)12.68%
EPS beat(4)4
Avg EPS beat(4)16.64%
Min EPS beat(4)11.76%
Max EPS beat(4)25.59%
EPS beat(8)7
Avg EPS beat(8)17.41%
EPS beat(12)8
Avg EPS beat(12)2.2%
EPS beat(16)11
Avg EPS beat(16)2.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.16%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.64%
EPS NY rev (1m)4.05%
EPS NY rev (3m)3.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.01
P/tB 5.01
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -100.52%
ROE -369.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.42%
ROA(5y)-56.3%
ROE(3y)-151.69%
ROE(5y)-107.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 2.09
Altman-Z -9.88
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.48%
EPS Next Y21.77%
EPS Next 2Y15.18%
EPS Next 3Y10.06%
EPS Next 5Y19.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.82%
EBIT Next 3Y-7.27%
EBIT Next 5Y-8.1%
FCF growth 1Y1.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.3%
OCF growth 3YN/A
OCF growth 5YN/A

PDS BIOTECHNOLOGY CORP / PDSB FAQ

Can you provide the ChartMill fundamental rating for PDS BIOTECHNOLOGY CORP?

ChartMill assigns a fundamental rating of 1 / 10 to PDSB.


What is the valuation status of PDS BIOTECHNOLOGY CORP (PDSB) stock?

ChartMill assigns a valuation rating of 0 / 10 to PDS BIOTECHNOLOGY CORP (PDSB). This can be considered as Overvalued.


How profitable is PDS BIOTECHNOLOGY CORP (PDSB) stock?

PDS BIOTECHNOLOGY CORP (PDSB) has a profitability rating of 0 / 10.


How financially healthy is PDS BIOTECHNOLOGY CORP?

The financial health rating of PDS BIOTECHNOLOGY CORP (PDSB) is 2 / 10.